Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Zimmer Biomet (ZBH) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider. This orthopedic device maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.05%. For the last reported quarter, Zimmer came ...

Zimmer Biomet Holdings, Inc. 2024年第一季度业绩预测 - Zimmer Biomet Holdings, Inc. (ZBH)将于5月2日在市场开盘前公布2024年第一季度业绩[1] - Zimmer Biomet在上一季度的盈利为2.20美元，超出了Zacks Consensus Estimate 2.3%[1] - Zimmer Biomet在过去四个季度中，盈利超过共识预期三次，平均超额收益率为4.99%[2] Zimmer Biomet业务挑战和展望 - Zimmer Biomet的业务受到供应挑战、劳动力市场困难和当前地缘政治局势等多重不利因素影响，导致利润率显著下降[3] - Zimmer Biomet预计在第一季度的传统业务中将见证手术量的提升，膝关节和髋关节业务的收入将受到强劲战略执行和创新的推动[4]

-- Zimmer Biomet Brings Joint Health Education and the Importance of Movement to America's Fastest-Growing Sport, Engaging the 48.3 Million Players, Fans of the Sport, and Raising Awareness as a Trusted Partner for Joint Replacement-- WARSAW, Ind., April 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced partnerships with three top pickleball organizations in the United States, becoming the first and only medical device partner for t ...

公司信息 - Zimmer Biomet Holdings, Inc.宣布将于2024年5月2日上午8:30在东部时间举行第一季度收益电话会议[1] - Zimmer Biomet是一家全球医疗技术领导者，拥有全面的产品组合，旨在最大程度地提高患者的活动能力和健康[4] 会议信息 - 可通过Zimmer Biomet的投资者关系网站https://investor.zimmerbiomet.com进行现场音频网络直播[2]

Zacks Premium - Zacks Premium提供多种方式帮助投资者充分利用股市和自信投资[1] Zacks Style Scores - Zacks Style Scores是与Zacks Rank一起开发的，根据价值、增长和动量特征对股票进行评级[3] 选择股票策略 - 通过Zacks Rank 1或2以及Style Scores A或B来选择股票，可以提高成功的可能性[12]

净销售额及利润 - 2023年，公司净销售额增长了6.5%，达到739.42亿美元[207] - 2023年，公司持续经营的净收益为10.24亿美元，较2022年增长了252.2%[208] - 2024年，公司预计净销售额将以中单位数增长，外汇汇率变化预计将对净销售额产生约0.5%的负面影响[209] 市场表现 - 2023年，美国市场净销售额增长了6.9%，国际市场净销售额增长了6.1%[213] 产品类别销售 - 2023年，膝关节和髋关节产品类别的净销售额分别增长了9.4%和3.8%[213] - 2023年，其他产品类别的净销售额增长了11.6%，主要归因于ROSA机器人的销售增长[219] 费用及成本 - 2023年，产品销售成本占净销售额的比例下降至28.2%，较2022年有所降低[220] - 2023年，研发费用和销售、一般及管理费用均有所增加，但销售、一般及管理费用占净销售额的比例有所下降[224][225] 公司运营及财务状况 - 2023年，公司未发生任何商誉或无形资产减值损失，与2022年相比减少了相关费用[226] - 2023年，公司实施了全球重组计划，旨在进一步简化组织结构，与营销策略更好地对齐，并在全球范围内降低成本[227] - 2023年，公司在EMEA地区的运营利润和运营利润占净销售额的比例均增加[236] - 2023年，公司的现金及现金等价物为4.158亿美元，可借款额度为10亿美元[239] - 2023年，公司从运营活动中获得的现金流为15.816亿美元，较2022年增加[241] - 2023年，公司用于投资活动的现金流为7.789亿美元，较2022年增加[242] - 公司于2023年通过股票回购计划回购了6.922亿美元的普通股[244] - 公司预计2023年重组计划将导致总税前费用为1.2亿至1.35亿美元[251] - 公司认为可以通过运营现金流、发行新债务和/或借款来满足债务偿还需求[247] - 公司于2023年四次宣布每股0.24美元的现金股利[249] - 公司于2023年用于投资活动的现金流主要用于产品组合的持续投资，包括新产品推出和制造网络的优化[243] 其他 - 库存和工具栏目会根据历史和预期需求模式评估当前库存水平[1] - 我们根据可实现净值对库存和工具进行减值[1] - 我们根据新信息对税务责任进行调整[2] - 我们在全球运营中处理复杂税法的不确定性[3] - 我们根据FASB关于所得税的指导原则确认税务责任[4]

ROSAShoulder系统介绍 - Zimmer Biomet宣布ROSAShoulder系统获得FDA 510(k)清关，成为全球首个用于肩关节置换手术的机器人手术助手[1] - ROSAShoulder系统是Zimmer Biomet公司综合ROSARobotics系列的第四个应用，旨在帮助外科医生利用机器人技术和数据分析执行高度复杂的肩部手术[1] - ROSAShoulder系统设计灵活，可执行全肩关节置换手术，支持精准放置以改善手术结果[1] - ROSAShoulder系统与Signature™ ONE手术规划系统2.0集成，提供三维图像可视化、手术规划和患者特定指南创建，帮助外科医生实时控制手术过程[1]

Zimmer Biomet (ZBH) is likely to grow in the coming quarters, backed by the implementation of meaningful strategic pillars within its Knee business. The company is benefitting from improved procedural volumes in a gradually stabilizing global musculoskeletal market. Zimmer Biomet is also bolstering its foothold in emerging markets for long-term growth opportunities, buoying optimism. Meanwhile, unfavorable solvency and an intense competitive landscape remain concerning for the company. In the past year, thi ...

WARSAW, Ind., Feb. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2024. The cash dividend of $0.24 per share is payable on or about April 30, 2024 to stockholders of record as of the close of business on March 29, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehens ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Styl ...